Search

Your search keyword '"Mørk, Cato"' showing total 161 results

Search Constraints

Start Over You searched for: Author "Mørk, Cato" Remove constraint Author: "Mørk, Cato"
161 results on '"Mørk, Cato"'

Search Results

1. Clinical consequences of infliximab immunogenicity and the effect of proactive therapeutic drug monitoring: exploratory analyses of the randomised, controlled NOR-DRUM trials

2. New, simplified versus standard photodynamic therapy (PDT) regimen for superficial and nodular basal cell carcinoma (BCC): A single-blind, non-inferiority, randomised controlled multicentre study.

3. Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial

5. HLA‐DQ2 is associated with anti‐drug antibody formation to infliximab in patients with immune‐mediated inflammatory diseases

7. List of Contributors

8. Risk factors for anti‐drug antibody formation to infliximab: Secondary analyses of a randomised controlled trial

10. Effect of Therapeutic Drug Monitoring vs Standard Therapy During Maintenance Infliximab Therapy on Disease Control in Patients With Immune-Mediated Inflammatory Diseases

11. Effect of Therapeutic Drug Monitoring vs Standard Therapy During Infliximab Induction on Disease Remission in Patients With Chronic Immune-Mediated Inflammatory Diseases

12. MOESM1 of Therapeutic drug monitoring of infliximab compared to standard clinical treatment with infliximab: study protocol for a randomised, controlled, open, parallel-group, phase IV study (the NOR-DRUM study)

26. List of Contributors

27. Therapeutic drug monitoring of infliximab compared to standard clinical treatment with infliximab: study protocol for a randomised, controlled, open, parallel-group, phase IV study (The NOR-DRUM study)

28. Infectious Pseudochromhidrosis: A Case Report and Literature Review.

29. 815 - Long-Term Efficacy and Safety of CT-P13 after Switching from Originator Infliximab: Exploratory Subgroup Analyses in IBD in the Nor-Switch Extension Trial

30. Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial

31. Biosimilar Infliximab (CT-P13) is not Inferior to Originator Infliximab: Explorative IBD Subgroup-Analyses in Crohn's Disease and Ulcerative Colitis from the Nor-Switch Trial

33. Specific changes in conduction velocity recovery cycles of single nociceptors in a patient with erythromelalgia with the I848T gain-of-function mutation of Nav1.7

35. Primary cutaneous posttransplant lymphoproliferative disorders in solid organ transplant recipients: A multicenter European case series

45. List of Contributors

48. Reply

49. Skin Pain and Discomfort in Psoriasis: An Exploratory Study of Symptom Prevalence and Characteristics.

50. Changes in Quality of Life in Persons with Eczema and Psoriasis After Treatment in Departments of Dermatology.

Catalog

Books, media, physical & digital resources